AnaptysBio (NASDAQ:ANAB) Given New $36.00 Price Target at JPMorgan Chase & Co.
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price decreased by equities research analysts at JPMorgan Chase & Co. from $66.00 to $36.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of […]
More Stories
Reconstruction and vital repairs underway in Syria, as ‘security conditions’ permit
Around 1.3 million Syrians have received food aid in the past three weeks across Syria from the UN and partners,...
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.5% – Time to Sell?
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.5% during trading on Tuesday . The stock traded...
Procter & Gamble (NYSE:PG) Stock Price Up 0.2% – Here’s Why
The Procter & Gamble Company (NYSE:PG – Get Free Report) traded up 0.2% on Tuesday . The stock traded as...
Vertiv (NYSE:VRT) Trading Down 4.4% – What’s Next?
Vertiv Holdings Co (NYSE:VRT – Get Free Report) fell 4.4% during mid-day trading on Tuesday . The company traded as...
Falcon Gold (CVE:FG) Trading Down 20% – What’s Next?
Falcon Gold Corp. (CVE:FG – Get Free Report)’s stock price was down 20% on Thursday . The company traded as...
Coca-Cola (NYSE:KO) Trading 1.5% Higher – Time to Buy?
The Coca-Cola Company (NYSE:KO – Get Free Report) traded up 1.5% on Tuesday . The stock traded as high as...